A Phase 3 interventional study of Rivoceranib and Placebo in Gastric Cancer and Gastric Adenocarcinoma, sponsored by Elevar Therapeutics. Completed at 95 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.
Sponsored by Elevar Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.
Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 3rd largest by enrollment, is one of 10 that started in 2017, is one of 9 in phase 3, and was the 16th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Jingdong Zhang · Sites in China
Ages 18+
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Zuoyi Jiao · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
Peking University Third Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 38 · Phase 3 13 · Phase 4 3
First in 2009; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 47 across the 57 interventional studies. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 57 have an industry lead sponsor. The 10 most frequent:
Elevar Therapeutics is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Elevar Therapeutics has 2 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing apatinib in Stomach Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07314203Phase 3Fujian Medical UniversityClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | 2027-08-25 |
| NCT03219593The First Affiliated Hospital of Bengbu Medical UniversityApatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing apatinib in Stomach Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Failure or intolerance to at least 2 prior lines of standard chemotherapies with each containing one or more of the following agents:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive rivoceranib 700 milligrams (mg) orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
Drug: Rivoceranib
Participants will receive matching placebo to rivoceranib orally once per day during each cycle plus BSC. BSC is defined as palliative, non-cancer therapy. Each cycle duration is 28 days.
Drug: Placebo
Oral tablet
Also known as: Apatinib
Oral tablet
Overall Survival (OS)
OS was defined as the time from randomization to death. Participants alive or lost to follow-up at the end of study (EOS) were censored.
Time frame: Day 1 (randomization) up to approximately 36 months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
PFS was defined as the time from randomization to either documented radiological progression or death from any cause. Participants alive and free of progression at the EOS were censored.
Time frame: Up to approximately 24 months
Objective Response Rate (ORR) Per RECIST 1.1
ORR was defined as the percentage of participants in the analysis population with the best overall response of Complete Response (CR: disappearance of all target lesions and reduction in short axis of any nodal target lesions to \<10 millimeter \[mm\]) or a Partial Response (PR: ≥30% decrease in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum diameters) per RECIST 1.1.
Time frame: Up to approximately 24 months
Disease Control Rate (DCR)
DCR was defined as the proportion of participants with a Best Overall Response of CR, PR, or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameter while on study) per RECIST 1.1.
Time frame: Up to approximately 24 months
Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 is a cancer specific Questionnaire with 30 questions for assessing the health-related QOL of cancer participants. The questionnaire incorporates 5 functional scales, 4 symptom scales, a global QOL scale, and single items for the assessment of additional systems commonly reported by cancer participants. All items are scored on 4-point Likert scales, ranging from 1 ('not at all') to 4 ('very much'), with the exception of 2 items in the global QOL scale which use modified 7-point linear analog scales. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicated greater functioning and for the symptom scales, a higher score indicated a greater symptom burden.
Time frame: Baseline, End of Treatment (EOT) (Up to 24 months)
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Stomach Cancer Specific (EORTC QLQ-STO22) Score
EORTC QLQ-STO22 is a 22-item gastric cancer-specific questionnaire-integrating system for assessing the health-related QOL of gastric cancer participants. Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicates greater functioning and for the symptom scales, a higher score indicates a greater symptom burden.
Time frame: Baseline, EOT (Up to 24 months)
Change From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score
EQ-5D-5L Questionnaire consists of EQ-5D-5L descriptive system and the visual analogue scale (VAS). The descriptive system comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
Time frame: Baseline, EOT (Up to 24 months)
Number of Participants Per QOL Dimension Response as Measured by the EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire
EQ-5D-5L Questionnaire comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels of response.
Time frame: EOT (Month 24)
| Milestone | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Extension Phase: Rivoceranib Plus BSC | Extension Phase: Placebo Plus BSC |
|---|---|---|---|---|
| Started | 308 | 152 | 0 | 0 |
| Received at least 1 dose of study drug | 307 | 151 | 0 | 0 |
| Completed | 52 | 28 | 0 | 0 |
| Not completed | 256 | 124 | 0 | 0 |
| Withdrew: Withdrawal by subject | 13 | 4 | 0 | 0 |
| Withdrew: Death | 232 | 110 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 7 | 0 | 0 |
| Withdrew: Physician decision | 7 | 2 | 0 | 0 |
| Withdrew: Study closed | 0 | 1 | 0 | 0 |
| Milestone | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Extension Phase: Rivoceranib Plus BSC | Extension Phase: Placebo Plus BSC |
|---|---|---|---|---|
| Started | 0 | 0 | 52 | 28 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 52 | 28 |
| Withdrew: Death | 0 | 0 | 34 | 16 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Study closed | 0 | 0 | 17 | 11 |
OS was defined as the time from randomization to death. Participants alive or lost to follow-up at the end of study (EOS) were censored.
| Months | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Overall Survival (OS) | 5.82 (5.26 to 6.47) | 5.13 (4.47 to 6.24) |
PFS was defined as the time from randomization to either documented radiological progression or death from any cause. Participants alive and free of progression at the EOS were censored.
| Months | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) | 2.83 (2.07 to 3.52) | 1.77 (1.71 to 1.84) |
ORR was defined as the percentage of participants in the analysis population with the best overall response of Complete Response (CR: disappearance of all target lesions and reduction in short axis of any nodal target lesions to \<10 millimeter \[mm\]) or a Partial Response (PR: ≥30% decrease in the sum of the longest diameters of the target lesions, taking as a reference the baseline sum diameters) per RECIST 1.1.
| Percentage of Participants | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Objective Response Rate (ORR) Per RECIST 1.1 | 6.5 (3.74 to 9.25) | 1.3 (0.16 to 4.67) |
DCR was defined as the proportion of participants with a Best Overall Response of CR, PR, or stable disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference the smallest sum diameter while on study) per RECIST 1.1.
| Percentage of Participants | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Disease Control Rate (DCR) | 40.3 (34.78 to 45.74) | 13.2 (7.78 to 18.53) |
EORTC QLQ-C30 is a cancer specific Questionnaire with 30 questions for assessing the health-related QOL of cancer participants. The questionnaire incorporates 5 functional scales, 4 symptom scales, a global QOL scale, and single items for the assessment of additional systems commonly reported by cancer participants. All items are scored on 4-point Likert scales, ranging from 1 ('not at all') to 4 ('very much'), with the exception of 2 items in the global QOL scale which use modified 7-point linear analog scales. A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicated greater functioning and for the symptom scales, a higher score indicated a greater symptom burden.
| units on a scale | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | -17.51 ± 22.72 | -18.01 ± 26.80 |
EORTC QLQ-STO22 is a 22-item gastric cancer-specific questionnaire-integrating system for assessing the health-related QOL of gastric cancer participants. Most questions use 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100. For the functioning scales, a higher score indicates greater functioning and for the symptom scales, a higher score indicates a greater symptom burden.
| units on a scale | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Body Image | 11.71 ± 29.95 | 9.43 ± 35.01 |
| Dyspnea | 16.64 ± 26.34 | 16.50 ± 24.91 |
| Pain | 12.72 ± 23.96 | 13.75 ± 21.91 |
| Reflux Symptoms | 11.46 ± 24.80 | 8.31 ± 21.73 |
| Eating Restrictions | 18.12 ± 26.45 | 17.76 ± 22.89 |
| Anxiety | 13.69 ± 23.64 | 10.55 ± 26.91 |
| Dry Mouth | 20.77 ± 33.22 | 11.56 ± 29.15 |
| Taste | 15.30 ± 32.46 | 14.48 ± 30.18 |
| Hair Loss | -15.37 ± 33.71 | -18.69 ± 30.05 |
EQ-5D-5L Questionnaire consists of EQ-5D-5L descriptive system and the visual analogue scale (VAS). The descriptive system comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.
| units on a scale | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Change From Baseline in EuroQol 5-Dimension 5-Level Visual Analogue Scale (EQ-5D-5L VAS) Score | -18.48 ± 19.11 | -15.36 ± 21.61 |
EQ-5D-5L Questionnaire comprises the 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each dimension has 5 levels of response.
| Participants | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Mobility: No problems | 46 | 27 |
| Mobility: Slight problems | 60 | 27 |
| Mobility: Moderate problems | 51 | 23 |
| Mobility: Severe problems | 43 | 17 |
| Mobility: Unable | 8 | 6 |
| Mobility: Missing | 100 | 52 |
| Self Care: No problems | 100 | 54 |
| Self Care: Slight problems | 47 | 22 |
| Self Care: Moderate problems | 40 | 10 |
| Self Care: Severe problems | 14 | 7 |
| Self Care: Unable | 7 | 7 |
| Self Care: Missing | 100 | 52 |
| Usual Activities: No problems | 36 | 24 |
| Usual Activities: Slight problems | 61 | 36 |
| Usual Activities: Moderate problems | 56 | 18 |
| Usual Activities: Severe problems | 43 | 13 |
| Usual Activities: Unable | 12 | 9 |
| Usual Activities: Missing | 100 | 52 |
| Pain/Discomfort: No pain or discomfort | 25 | 13 |
| Pain/Discomfort: Slight pain or discomfort | 61 | 36 |
| Pain/Discomfort: Moderate pain or discomfort | 67 | 26 |
| Pain/Discomfort: Severe pain or discomfort | 47 | 19 |
| Pain/Discomfort: Extreme pain or discomfort | 8 | 6 |
| Pain/Discomfort: Missing | 100 | 52 |
| Anxiety/Depression: Not anxious or depressed | 49 | 26 |
| Anxiety/Depression: Slightly anxious or depressed | 60 | 36 |
| Anxiety/Depression: Moderately anxious or depressed | 62 | 25 |
| Anxiety/Depression: Severely anxious or depressed | 29 | 8 |
| Anxiety/Depression: Extremely anxious or depressed | 8 | 5 |
| Anxiety/Depression: Missing | 100 | 52 |
Collected over Up to approximately 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivoceranib Plus Best Supportive Care (BSC) | 283/307 (92.2%) | 149/307 (48.5%) | 299/307 (97.4%) |
| Placebo Plus BSC | 134/151 (88.7%) | 66/151 (43.7%) | 140/151 (92.7%) |
| Event | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| AstheniaGeneral disorders | 8/307 | 8/151 |
| Abdominal painGastrointestinal disorders | 15/307 | 3/151 |
| IleusGastrointestinal disorders | 5/307 | 4/151 |
| CholangitisHepatobiliary disorders | 2/307 | 4/151 |
| Decreased appetiteMetabolism and nutrition disorders | 8/307 | 4/151 |
| PneumoniaInfections and infestations | 8/307 | 0/151 |
| DysphagiaGastrointestinal disorders | 3/307 | 3/151 |
| Tumour haemorrhageNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/307 | 3/151 |
| PyrexiaGeneral disorders | 6/307 | 1/151 |
| VomitingGastrointestinal disorders | 5/307 | 2/151 |
| Event | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC |
|---|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 132/307 | 45/151 |
| HypertensionVascular disorders | 106/307 | 5/151 |
| DiarrhoeaGastrointestinal disorders | 92/307 | 22/151 |
| ProteinuriaRenal and urinary disorders | 90/307 | 11/151 |
| AnaemiaBlood and lymphatic system disorders | 64/307 | 41/151 |
| AstheniaGeneral disorders | 83/307 | 30/151 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 81/307 | 6/151 |
| Abdominal painGastrointestinal disorders | 78/307 | 30/151 |
| FatigueGeneral disorders | 77/307 | 16/151 |
| NauseaGastrointestinal disorders | 72/307 | 34/151 |
The Intent to Treat (ITT) set consists of data from all participants who were randomized. In the ITT set, participants were included in the group to which they were randomized.
| Age, Continuous(years) | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Total |
|---|---|---|---|
| Mean | 60.03 ± 11.11 | 59.96 ± 10.63 | 60.01 ± 10.94 |
| Sex: Female, Male(Participants) | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Total |
|---|---|---|---|
| Female | 67 | 40 | 107 |
| Male | 241 | 112 | 353 |
| Ethnicity (NIH/OMB)(Participants) | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 5 |
| Not Hispanic or Latino | 303 | 152 | 455 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rivoceranib Plus Best Supportive Care (BSC) | Placebo Plus BSC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 207 | 105 | 312 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 100 | 46 | 146 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Feb 2019, 23 months.
Results were first posted in Jul 2022, 3 years 4 months after primary completion.
Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 23 months is below that.
Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apatinib
Elevar Therapeutics